Clinical trials: Glucagon
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
A randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus (T1DM)
- Trial name
- NCT03895697
- Testing
- dasiglucagon
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypoglycemia, Complications of Bariatric Procedures
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe…
- Trial name
- NCT02733588
- Testing
- G-Pump™ (glucagon infusion)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes Mellitus
A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
This is a study to assess the pharmacokinetics, safety, and tolerability of sequential single oral doses of MK-8093 10 mg, 40 mg, 200 mg, or placebo to MK-8093 (Part 1) depending on treatment assignment in young healthy male…
- Trial name
- NCT02012166
- Testing
- MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
- Trial name
- NCT02589626
- Testing
- empagliflozin 10mg, empagliflozin 25 mg
- Where
- 16 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
glp1 Agonist, Gene Expression
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared…
- Conditions
- glp1 Agonist, Gene Expression, Skin Laxity
- Trial name
- NCT07224880
- Testing
- ellacor
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Cytrellis Biosystems, Inc.
Hypoglycemia, Diabetes Mellitus, Type 1
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo
- Trial name
- NCT03688711
- Testing
- Dasiglucagon
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Zealand Pharma
Hypoglycemia
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.
- Trial name
- NCT00745186
- Testing
- Glucagen, Mayne Glucagon
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Tofogliflozin GLP-1 Analogue Combination Trial
An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.
- Trial name
- NCT02537834
- Testing
- Tofogliflozin, GLP-1 analogue
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Kowa Company, Ltd.
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing…
- Trial name
- NCT07685808
- Testing
- Olatorepatide
- Where
- 21 sites in United States
- Volunteers
- 360 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy Adult Subject, Overweight Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects.
- Trial name
- NCT06601517
- Testing
- Repaglinide, Atorvastatin, Digoxin
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Hypoglycemia
Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon
The trial is a single-centre, randomized, double-blind, parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c.
- Trial name
- NCT02660008
- Testing
- ZP4207, GlucaGen
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study.
- Trial name
- NCT02402933
- Testing
- Nasal Glucagon
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Obesity
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with…
- Trial name
- GZBF (NCT07467447)
- Testing
- Retatrutide (LY3437943), Standardized diet and physical activity counseling throughout the study.
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Hudson Biotech
Diabetes Mellitus, Type 1
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D.
- Trial name
- NCT06588504
- Testing
- Dasiglucagon, Glucagon
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study.
- Conditions
- Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
- Trial name
- NCT02171130
- Testing
- Nasal Glucagon
- Where
- 9 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 1
ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
The trial is a single-centre, randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon*) administered subcutaneously to patients with type 1…
- Trial name
- NCT02916251
- Testing
- ZP4207(dasiglucagon) glucagon analogue, Glucagon (Native glucagon)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Zealand Pharma
Blood Sugar; High, Overweight and Obesity
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1
- Trial name
- RCT (NCT07141472)
- Testing
- GB
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Lawry Han